Navigation Links
ICON and MedAvante Sign Alliance Agreement
Date:3/16/2009

Partnership Aims To Enhance Precision and Reduce High Failure Rates in Central Nervous System Clinical Trials

DUBLIN and Hamilton, N.J., March 16 /PRNewswire-FirstCall/ -- ICON (Nasdaq: ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries and MedAvante, Inc. the leader in centralized psychiatric patient evaluation, today announced that they have signed an alliance agreement. This agreement will couple ICON's global reach and proven excellence in clinical trial management with MedAvante's innovative platform to centralize and calibrate the assessment of patients undergoing treatment in clinical trials. As a result, pharmaceutical and biotechnology trial sponsors will be able to reliably and precisely measure patients' response to therapies.

"MedAvante has developed a platform that addresses a major cause of clinical trial failure in Central Nervous System (CNS) development: variability in both clinical diagnosis of the disorder being studied and ongoing assessment of the severity of the patient's symptoms in a consistent and standardized fashion," says Dr. John Hubbard, President, ICON Clinical Research. "ICON is constantly striving to offer our pharmaceutical and biotechnology partners innovative clinical trial solutions to enhance the drug development process."

"ICON is a proven leader in the provision of high quality clinical research services," says Paul Gilbert, Chief Executive Officer of MedAvante. "This alliance extends our ability to offer our services across the industry and across the globe. Most importantly, however, is what this alliance provides to CNS drug developers: The ability on a larger scale to reduce the high rate of failed CNS clinical trials which the industry recognizes as unacceptable in terms of cost and lost time."

About ICON

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the strategic development, management and analysis of programs that support clinical development -- from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 71 locations in 38 countries and has approximately 7,000 employees. Further information is available at www.iconplc.com.

About MedAvante

MedAvante is a global provider of centralized expert psychological rating services to the pharmaceutical, biotechnology, and medical device industries. MedAvante is a pioneer in developing a solution for one of the most intractable problems in CNS clinical trials: the high rate of uninformative or failed studies. MedAvante applies unique methods to systematically remove potential sources of bias and variability from the assessment process. By centralizing assessments with expert, standardized, objective, clinical interviewers over MedAvante's 2-way, real-time, high quality video-conferencing, MedAvante makes subjective assessments of drug efficacy increasingly objective. As a result, sponsors can achieve increased study power and reduced trial-failure rates, enabling them to bring more effective CNS drugs to market sooner. MedAvante operates facilities in Hamilton, NJ; Los Angeles, CA; and Madison, WI. For more information about MedAvante, visit www.medavante.net.


'/>"/>
SOURCE ICON
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
2. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
3. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
4. Lung Cancer Alliance Hails Announcement of New Erbitux(R) Data
5. Lung Cancer Alliance Commends NCCN on Screening Guidelines
6. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
7. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
8. Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
9. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
10. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
11. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... Lori R. Somekh, founder of the Law Office of ... elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain ... to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris F. ... AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking place ... the field of medical informatics, this prestigious award is presented to an individual whose ...
Breaking Medicine News(10 mins):